JP Morgan Maintains Overweight Rating and Raises Price Target for Seaport Therapeutics
JP Morgan has maintained its 'Overweight' rating on Seaport Therapeutics, Inc. and increased its price target from $40 to $41.
Stocks · News reference
This Entegris Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Analysts initiated coverage on VYLR, IMTX, ENTG, SLGL and SPTX, assigning Neutral, Buy or Overweight ratings and price targets.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Sol-Gel Technologies Scheduled to Announce Q3 2026 Financial Results
Sol-Gel Technologies is scheduled to release its financial results for the third quarter of 2026 on November 5, 2026.
Automatic FOUP Opener Market - Global Forecast 2026-2032 | Fab Automation and Contamination Control Drive 5.36% CAGR and a USD 6.04 Billion Opportunity by 2032
The global Automatic FOUP Opener market is projected to grow from USD 4.41 billion in 2026 to USD 6.04 billion by 2032, expanding at a CAGR of 5.36%. Growth is driven by increasing fab automation, contamination control requirements, and demand for consistent wafer handling in semiconductor manufacturing. Key trends include AI-enabled predictive maintenance, modular designs, and enhanced interoperability with factory control systems.
Entegris Completes Acquisition of Advanced Abrasives Corporation and Expands into Thermal Management Materials
Entegris has acquired Advanced Abrasives Corporation and announced a strategic expansion into silicon carbide and diamond-enabled thermal management materials for AI advanced packaging.
Entegris Enters Silicon Carbide and Diamond-Enabled Thermal Management Materials Market
Entegris has announced its entry into the market for silicon carbide and diamond-enabled thermal management materials, specifically targeting AI advanced packaging applications.
Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Clinical Progress
Seaport Therapeutics announced its third-quarter 2026 financial results, reporting a net loss of $26.4 million and highlighting key clinical milestones for its Glyph platform candidates.